Akari Therapeutics PLC (AKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.54M
Last updated: Nov 17, 2026 at 10:59 AM ET
Akari Therapeutics PLC (AKTX) Competitors
The companies most similar to Akari Therapeutics are Marker Therapeutics (MRKR), Plus Therapeutics (PSTV) and Pluri (PLUR). By market cap, Akari Therapeutics ranks 7th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.
Peer Comparison
AKTX's revenue growth of 0.0% is above the peer median of -1.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Akari Therapeutics (AKTX) | $15.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cyclerion Therapeutics Inc (CYCN) | $15.73M | N/A | N/A | 0.0% | N/A | -43.2% | 0.00% |
| Cocrystal Pharma Inc (COCP) | $18.88M | N/A | 39.2x | 0.0% | N/A | 26.9% | 0.00% |
| Chemomab Therapeutics Ltd DRC (CMMB) | $12.31M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Estrella Immunopharma Inc. (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biocardia Inc (BCDA) | $12.58M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Seres Therapeutics Inc (MCRB) | $14.27M | N/A | 6.6x | 0.0% | N/A | 68.9% | 0.00% |
| Fractyl Health, Inc. Common Stock (GUTS) | $11.99M | N/A | N/A | 0.0% | -245.8% | -57.1% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $15.41M | N/A | 8.7x | 0.0% | -650.8% | -1.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Akari Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| Cyclerion Therapeutics Inc (CYCN) | Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development... | |
| Cocrystal Pharma Inc (COCP) | Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic... | COCP competitors |
| Chemomab Therapeutics Ltd DRC (CMMB) | Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. | CMMB competitors |
| Estrella Immunopharma Inc. (ESLA) | Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. | ESLA competitors |
| Biocardia Inc (BCDA) | BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. | BCDA competitors |
| Seres Therapeutics Inc (MCRB) | Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally... | MCRB competitors |
| Fractyl Health, Inc. Common Stock (GUTS) | Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. | GUTS competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
Frequently Asked Questions About AKTX
Who are Akari Therapeutics' main competitors?
The companies most similar to Akari Therapeutics include Marker Therapeutics (MRKR), Plus Therapeutics (PSTV), Pluri (PLUR), Context Therapeutics (CNTX) and Cyclerion Therapeutics (CYCN), listed from the closest match.
Who is Akari Therapeutics' biggest competitor?
Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Marker Therapeutics (MRKR) is the closest match by business profile, size, sector and industry.
How does AKTX stock compare with its competitors?
AKTX's net margin is 0.0% against a peer median of 0.0%.
Which of Akari Therapeutics' competitors pays a higher dividend?
Akari Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Akari Therapeutics bigger than its competitors?
No. Akari Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.
AKTX pages: Overview, Earnings, Forecast, Financials, Competitors